North America Radiotherapy Market Report

North America Radiotherapy Market Size

The North America Radiotherapy Market is projected to grow from USD 2.35 billion in 2024 to USD 3.82 billion by 2033, at a CAGR of 5.54%.

Radiotherapy, or radiation therapy, is a critical component of modern oncology, utilizing ionizing radiation to manage and treat malignant tumors. In North America, this market encompasses a wide range of technologies including external beam radiotherapy, brachytherapy, and systemic radiation therapy, deployed across hospitals, specialty clinics, and ambulatory surgical centers. The region remains at the forefront of advanced cancer care, supported by robust healthcare infrastructure, high patient awareness, and ongoing technological innovations.

According to the American Cancer Society, in 2024, over 1.9 million new cancer cases were projected to be diagnosed in the United States alone, with more than half of all cancer patients receiving some form of radiation therapy during their treatment course. Canada also reports a significant burden of cancer, with approximately 238,000 new cases estimated for the same year as per the Canadian Cancer Society. These figures underscore the growing demand for radiotherapy services across the continent.

The integration of precision medicine, image-guided systems, and artificial intelligence has further enhanced treatment accuracy and minimized collateral damage to healthy tissues. As per the National Cancer Institute, advancements such as proton therapy and stereotactic body radiation therapy (SBRT) have seen increased adoption in recent years.

MARKET DRIVERS

Rising Incidence of Cancer Across North America

The escalating prevalence of cancer is one of the most compelling drivers behind the growth of the North America radiotherapy market. According to the American Cancer Society, approximately 60% of all cancer patients in the U.S. receive radiation therapy as part of their treatment regimen. With an aging population and lifestyle-related risk factors contributing to rising cancer rates, the demand for effective therapeutic interventions has surged. In 2024 alone, over 1.9 million new cancer cases were expected to be diagnosed in the U.S., reflecting a steady upward trend from previous years.

In Canada, cancer incidence is similarly on the rise. As per the Canadian Cancer Society, about 238,000 new cancer cases were projected for 2024, with lung, breast, colorectal, and prostate cancers being the most prevalent. Given that radiotherapy is often used in conjunction with surgery and chemotherapy, its role in multimodal treatment strategies has become indispensable.

Moreover, early diagnosis initiatives and improved screening programs have led to higher detection rates, further fueling the need for targeted therapies. For instance, mammography and low-dose CT scans have significantly increased early-stage cancer detection, where localized treatments like radiotherapy are particularly effective. This growing disease burden continues to drive sustained demand across the North American healthcare landscape.

Technological Advancements in Radiation Therapy Equipment

Technological innovation has been a cornerstone of the North America radiotherapy market’s expansion. The development and adoption of highly precise and minimally invasive radiation delivery systems have transformed cancer treatment paradigms. Advanced modalities such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and proton therapy have significantly improved treatment outcomes, enabling clinicians to deliver higher doses of radiation with greater accuracy while sparing surrounding healthy tissue.

Proton therapy, though still relatively niche due to high capital costs, has seen growing adoption, with more than 40 proton therapy centers operational across the U.S. as of 2024, as per the National Association for Proton Therapy.

Apart from these, the integration of artificial intelligence (AI) and machine learning into treatment planning systems has optimized dose calculations and reduced human error. Major players such as Varian Medical Systems and Elekta have launched AI-driven platforms that enhance workflow efficiency and improve patient outcomes. The U.S. Food and Drug Administration (FDA) has approved several such technologies in recent years, accelerating their integration into clinical practice. These advancements are driving sustained market growth across North America.

MARKET RESTRAINTS

High Cost of Advanced Radiotherapy Equipment and Treatments

The substantial financial burden associated with acquiring and operating advanced radiation therapy equipment is a significant restraint affecting the North America radiotherapy market. Cutting-edge technologies such as proton therapy systems can cost upwards of $150 million to install, according to the National Association for Proton Therapy. These exorbitant setup costs limit widespread adoption, especially among smaller hospitals and community-based cancer centers.

Beyond capital expenditure, the operational expenses of maintaining sophisticated radiotherapy units are considerable. Specialized personnel, shielding infrastructure, and regular calibration add to the long-term financial commitment required. Besides, the complexity of newer systems necessitates extensive training for medical physicists and radiation therapists, further inflating labor costs.

Insurance coverage disparities also play a role in limiting patient access. While Medicare and major private insurers typically cover conventional radiation therapy, reimbursement for newer modalities like proton therapy can be inconsistent. As per a study published in JAMA Oncology, nearly 20% of proton therapy claims were denied by commercial payers between 2019 and 2022. These financial barriers hinder equitable access to advanced treatments and slow down the overall market expansion in certain regions across North America.

Shortage of Skilled Radiation Oncology Professionals

The shortage of trained professionals essential for delivering radiation therapy effectively is a persistent challenge within the North America radiotherapy market. Radiation oncologists, medical physicists, dosimetrists, and radiation therapists are all integral to the safe and accurate administration of treatment. However, workforce shortages in these disciplines have increasingly constrained service capacity, particularly in rural and underserved areas. The situation is exacerbated by the uneven geographic distribution of practitioners, with many rural counties lacking access to any radiation therapy facility. Canada also experiences similar challenges. As per the Canadian Association of Radiation Oncology (CARO), there is a growing imbalance between the number of radiation therapy graduates and available clinical positions, leading to underemployment and brain drain. These staffing constraints delay treatment initiation, reduce clinic throughput, and ultimately hinder the scalability of advanced radiotherapy services across the continent.

MARKET OPPORTUNITIES

Expansion of Telehealth and Remote Radiotherapy Planning Services

The integration of telehealth and remote treatment planning solutions is an emerging opportunity within the North America radiotherapy market. As digital health technologies mature, they offer innovative ways to overcome geographical barriers and enhance access to specialized radiation oncology services. Telehealth enables real-time consultations between patients and oncologists, while remote planning allows medical physicists and dosimetrists to design radiation treatment plans from off-site locations.

According to the American Society for Radiation Oncology (ASTRO), remote treatment planning has already demonstrated clinical viability, particularly in rural and resource-limited settings. Studies indicate that cloud-based platforms facilitate seamless data sharing, allowing multidisciplinary teams to collaborate efficiently without requiring physical proximity.

Moreover, the U.S. Department of Health and Human Services (HHS) expanded telehealth flexibilities post-pandemic, encouraging broader adoption of virtual oncology services. This regulatory shift provides a conducive environment for remote radiotherapy consultations and follow-ups, particularly beneficial for elderly and mobility-challenged patients.

Increasing Investment in Research and Development of Radiopharmaceuticals

The expanding research and development efforts in radiopharmaceuticals is another promising avenue for growth in the North America radiotherapy market. These compounds, which combine radioactive isotopes with targeting molecules, are gaining prominence in both diagnostic imaging and therapeutic applications, particularly in the treatment of advanced cancers such as neuroendocrine tumors and prostate cancer.

According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), investment in radiopharmaceutical R&D has surged in recent years, with over $3 billion allocated globally in 2023, a significant portion of which came from North American biotech and pharmaceutical firms. Companies like Novartis, Bayer, and Point Biopharma have accelerated clinical trials for novel alpha-emitting therapeutics, such as lutetium-177 (Lu-177) and actinium-225 (Ac-225), which offer targeted radiation delivery with minimal side effects.

The U.S. Food and Drug Administration (FDA) has recognized this momentum, approving multiple radiopharmaceutical therapies in recent years, including Pluvicto (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer in 2022. These approvals reflect growing confidence in the efficacy of precision radiotherapy approaches.

MARKET CHALLENGES

Regulatory Complexity and Reimbursement Barriers

The intricate regulatory landscape and inconsistent reimbursement policies is a key challenge impeding the growth of the North America radiotherapy market. Radiation therapy devices and procedures must undergo rigorous approval processes by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada. These evaluations, while essential for ensuring safety and efficacy, can result in lengthy delays before new technologies reach clinical settings.

For instance, the FDA’s Premarket Approval (PMA) pathway for high-risk medical devices can take anywhere from 12 to 36 months, according to the FDA’s own performance metrics. This extended timeline hampers the rapid deployment of innovative solutions, particularly in fast-evolving fields such as proton therapy and adaptive radiotherapy. Similarly, Health Canada’s review process, although streamlined through the Expedited Review Pathway, still presents hurdles for smaller manufacturers seeking market entry.

Reimbursement inconsistencies further complicate adoption. Medicare and Medicaid Services (CMS) reimbursements for radiotherapy vary based on site of service, modality, and geographic location. Private insurers often impose restrictive prior authorization requirements, particularly for newer techniques like stereotactic body radiation therapy (SBRT) and proton therapy. These regulatory and financial barriers deter investment and delay patient access, posing a significant challenge to the market’s expansion trajectory.

Patient Access Disparities Across Rural and Urban Settings

Despite North America’s advanced healthcare infrastructure, significant disparities persist in patient access to radiotherapy services between urban and rural populations. Geographic location plays a critical role in determining whether patients receive timely and appropriate radiation treatment. According to the American Society for Radiation Oncology (ASTRO), nearly 20% of U.S. counties lack a single radiation therapy facility, disproportionately affecting rural communities.

As per the data from the National Cancer Institute (NCI), patients residing in rural areas are 10% less likely to receive radiotherapy compared to their urban counterparts. This gap is partly attributed to limited transportation options, fewer local oncology specialists, and longer referral times. According to a study published in Cancer journal found that rural cancer patients travel an average of 56 miles for radiation therapy, compared to just 12 miles for urban patients.

In Canada, similar patterns emerge. These disparities contribute to delayed treatment initiation, poorer clinical outcomes, and lower survival rates among rural populations. Efforts to deploy mobile radiation therapy units and expand telemedicine services have shown promise, yet logistical and funding constraints remain.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The External Beam Radiation Therapy (EBRT)segment dominated the North America radiotherapy market by accounting for 65.6% of total revenue in 2024. Its widespread adoption across major cancer treatment centers and hospitals, where it serves as a first-line therapy for a wide range of malignancies including prostate, breast, lung, and head and neck cancers, is one of the major factors driving the growth of EBRT segment.

The growing prevalence of these cancers has significantly fueled demand for EBRT. According to the American Cancer Society, more than 1.9 million new cancer cases were expected to be diagnosed in the U.S. in 2024, with over half of all patients receiving radiation therapy at some point during their treatment.

Technological advancements have further strengthened EBRT’s position. The integration of image-guided systems, such as Cone Beam CT, has enhanced precision, allowing for real-time tumor tracking and reduced damage to surrounding healthy tissue. Further, the expansion of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) into non-traditional indications like early-stage lung cancer and brain metastases has broadened the clinical scope of EBRT.

Reimbursement support from both public and private payers, particularly in the U.S., also contributes to its leading market position. Medicare covers approximately 80% of EBRT costs under Part B, ensuring accessibility for elderly patients who form a significant portion of cancer cases.

The systemic radiation therapy segment is emerging as the fastest-growing segment in the North America radiotherapy market, projected to expand at a CAGR of over 11% from 2025 to 2033. The increasing adoption of radiopharmaceuticals, especially in the treatment of advanced-stage cancers such as neuroendocrine tumors and metastatic prostate cancer is rapidly expanding the progress of systemic radiation therapy segment.

A further key driver behind this surge is the approval and clinical success of targeted radionuclide therapies. Lutetium-177 (Lu-177) based treatments like Pluvicto (developed by Novartis) have demonstrated significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the U.S. Food and Drug Administration (FDA), Pluvicto was associated with a 38% reduction in the risk of death compared to standard therapies, prompting rapid uptake across oncology practices.

Apart from these, the rise in nuclear medicine infrastructure supports systemic therapy adoption. Research funding and pharmaceutical investments are also accelerating innovation. Companies such as Bayer, Point Biopharma, and Telix Pharmaceuticals are advancing alpha-emitting agents like Actinium-225 and Radium-223, which offer potent cell-killing capabilities with minimal off-target toxicity. These developments signal a paradigm shift toward personalized, molecularly guided radiation therapy, positioning systemic radiation therapy as a high-growth sector within the broader market.

By Application Insights

The prostate cancer segment represented the largest application in the North America radiotherapy market by capturing a 22.2% of total share in 2024. The high incidence of prostate cancer, coupled with the effectiveness of radiation therapy as a primary or adjuvant treatment modality is mainly driving the prostate cancer segment. According to the American Cancer Society, prostate cancer is the most commonly diagnosed cancer among men in the United States, with an estimated 299,000 new cases expected in 2024 alone. Over 40% of these patients receive external beam radiation therapy (EBRT) or brachytherapy as part of their treatment plan, making it one of the most widely utilized applications of radiotherapy in the region. The aging demographic profile in North America further fuels this trend. With nearly 17% of the U.S. population aged 65 or older, as per the U.S. Census Bureau, the risk of developing prostate cancer increases significantly. Early detection through PSA screening and digital exams has improved diagnosis rates, enabling timely intervention with radiation-based therapies. In addition, technological advancements such as Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT) have enhanced treatment precision while minimizing side effects. According to a study published in JAMA Oncology found that SBRT achieved comparable five-year survival outcomes to surgery in localized prostate cancer, reinforcing its clinical acceptance. Moreover, favorable reimbursement policies from both public and private insurers support widespread access. These factors collectively sustain prostate cancer as the leading application area for radiotherapy in North America.

The Lung cancer is the fastest-growing application segment in the North America radiotherapy market, projected to grow at a CAGR of over 10% between 2024 and 2030. The rising lung cancer incidence, improvements in early detection methods, and the expanding use of stereotactic body radiation therapy (SBRT) in treating early-stage disease is fuelling the swift development of lung cancer segment. According to the American Cancer Society, lung cancer remains the leading cause of cancer-related deaths in the U.S., with approximately 234,500 new cases diagnosed in 2024. Smoking cessation programs and increased awareness have contributed to a gradual decline in mortality; however, late-stage diagnosis remains common, necessitating effective treatment strategies. Also, the adoption of SBRT for medically inoperable early-stage lung cancer is another significant developments fueling this growth of segment. As per Studies from the National Cancer Institute, SBRT achieves local control rates exceeding 90% in stage I non-small cell lung cancer (NSCLC), making it a preferred alternative for patients unfit for surgery.

The expansion of low-dose CT (LDCT) screening programs has also played a pivotal role. Pharmaceutical and biotech companies are investing heavily in combination therapies involving immunotherapy and radiation. Clinical trials have shown synergistic effects when PD-1 inhibitors are combined with radiation, enhancing immune response against tumor cells. These advancements position lung cancer as a rapidly evolving and high-potential application segment within the North American radiotherapy landscape.

By Equipment Type Insights

The Linear accelerators (LINACs) depicted the strongest equipment type in the North America radiotherapy market by accounting for 68.1% of total revenue in 2024. Their versatility in delivering various forms of external beam radiation therapy, including IMRT, VMAT, and SBRT, making them indispensable in modern radiation oncology departments, is supporting the dominance of LINAC segment. Also, their widespread adoption is supported by continuous technological upgrades, such as onboard imaging systems and real-time motion tracking, which enhance treatment accuracy and reduce collateral damage to surrounding tissues. The high prevalence of cancer in North America further drives demand for LINAC units. As per the American Cancer Society, more than 1.9 million new cancer cases were expected in the U.S. in 2024, with over half of these patients requiring radiation therapy at some point in their treatment journey. Given that LINACs are the backbone of most radiation therapy delivery systems, their presence in both large academic institutions and community-based clinics continues to grow. Major manufacturers such as Varian Medical Systems, Elekta, and Accuray Incorporated have introduced AI-integrated LINAC platforms, enhancing automation and workflow efficiency. For instance, Varian’s Ethos system enables adaptive radiation therapy in a single session, reducing planning time and improving patient outcomes. The U.S. Food and Drug Administration (FDA) approved several next-generation LINAC models in recent years, facilitating faster clinical integration. Moreover, reimbursement policies remain favorable for LINAC-based treatments. Medicare coverage ensures accessibility for elderly patients, who constitute a significant proportion of cancer cases.

The Treatment Planning Systems (TPS) are experiencing the fastest growth within the North America radiotherapy equipment market, projected to expand at a CAGR of over 9% in the coming years. The increasing complexity of radiation therapy techniques, which require highly accurate dose calculations and anatomical modelling is one of the main reasons behind the quick growth of TPS segment.

Modern treatment planning relies heavily on artificial intelligence (AI) and machine learning algorithms to optimize radiation delivery. Companies such as RaySearch Laboratories and Mitsubishi Electric have developed cloud-based TPS platforms that enable remote collaboration among oncologists, physicists, and dosimetrists.The adoption of advanced modalities such as proton therapy and stereotactic radiosurgery has further amplified demand for sophisticated treatment planning tools. Besides, regulatory agencies are promoting digital transformation in radiation oncology. The U.S. Food and Drug Administration (FDA) has accelerated approvals for AI-driven planning software, recognizing their potential to improve treatment quality and consistency. As healthcare providers prioritize efficiency and precision, investment in next-generation treatment planning systems is expected to continue rising, positioning this segment as a key growth driver in the North American radiotherapy market.

COUNTRY LEVEL ANALYSIS

The United States secured the dominant position in the North America radiotherapy market by accounting for 83.6% of the regional share in 2024. This lead position is attributed to the country’s high cancer incidence, robust healthcare infrastructure, and substantial investments in oncology research and technology. The aging population, lifestyle-related risk factors, and increased cancer screening initiatives have contributed to higher diagnosis rates, driving demand for advanced treatment options. The U.S. also leads in the adoption of cutting-edge technologies such as proton therapy, stereotactic body radiation therapy (SBRT), and AI-integrated treatment planning systems. Reimbursement support from both public and private payers further sustains market growth. Medicare covers a significant portion of radiation therapy costs. Further, the FDA’s expedited review process for innovative radiation devices has enabled faster commercialization of novel therapies, reinforcing the U.S. as a global leader in radiotherapy innovation and clinical adoption.

Canada is positioning it as the second-largest contributor after the United States. This share reflects Canada’s well-developed healthcare system, high patient awareness, and increasing investment in cancer care infrastructure. According to the Canadian Cancer Society, an estimated 238,000 new cancer cases were expected in Canada in 2024, with prostate, breast, colorectal, and lung cancers being the most prevalent. Radiation therapy plays a crucial role in managing these conditions, with over 50% of cancer patients receiving some form of radiotherapy during their treatment course. The country has made significant strides in adopting advanced radiation therapy technologies. Despite these advancements, challenges persist regarding geographic disparities in access. However, government initiatives aimed at expanding telehealth and mobile radiation units are helping bridge these gaps. Furthermore, Canada benefits from strong academic and clinical research networks. Institutions such as the University of Toronto and McGill University are actively involved in radiopharmaceutical development and AI-driven treatment planning, contributing to long-term market growth. These factors collectively reinforce Canada’s position as a key player in the North American radiotherapy landscape.

The Rest of North America, comprising Mexico and select Caribbean territories, holds a smaller but growing share of the regional radiotherapy market. While still in the early stages of development compared to the U.S. and Canada, this segment presents untapped opportunities due to rising cancer incidence and gradual improvements in healthcare infrastructure. Despite this burden, access to radiotherapy remains limited. Efforts to expand cancer care capacity are gaining momentum. The Mexican government has launched initiatives to modernize oncology services, including the establishment of new radiation therapy centers in underserved regions. Similarly, in the Caribbean, countries such as Puerto Rico and Jamaica are investing in upgraded radiation therapy infrastructure to meet growing patient demand. While economic constraints and regulatory hurdles remain, the Rest of North America is gradually emerging as a prospective growth area for the radiotherapy market, offering long-term potential for international medical equipment suppliers and service providers.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Companies playing a promising role in the North America radiotherapy market profiled in this report are Nordion Inc., RaySearch Laboratories AB, Ion Beam Applications SA, C. R. Bard Inc., Mevion Medical Systems Inc., Varian Medical Systems Inc., IsoRay Medical Inc., Elekta AB, Accuray Incorporated and Mitsubishi Electric Corporation.

The competition in the North America radiotherapy market is marked by a dynamic mix of established players and emerging innovators striving to capture a larger share of the rapidly evolving oncology space. With rising cancer incidence and growing demand for precision treatments, companies are intensifying efforts to differentiate themselves through technological superiority and enhanced clinical workflows. The market is witnessing a shift towards AI-integrated platforms, real-time imaging, and adaptive therapies that allow for more personalized treatment approaches. While major corporations dominate through extensive product portfolios and strong distribution networks, smaller firms are leveraging niche innovations to carve out specialized positions. Strategic partnerships, regulatory approvals, and investment in R&D play a crucial role in maintaining competitiveness. Apart from these, as healthcare providers seek cost-effective yet advanced solutions, vendors are focusing on optimizing treatment efficiency and minimizing operational complexities. This evolving landscape fosters continuous advancement, ensuring that North America remains at the forefront of global radiotherapy innovation.

Top Players in the Market

Varian Medical Systems (A Siemens Healthineers Company)
Varian, now part of Siemens Healthineers, is a global leader in cancer care solutions, particularly in radiotherapy. The company offers a comprehensive portfolio including linear accelerators, treatment planning systems, and software for precision oncology. Known for its innovative platforms like Ethos therapy and Halcyon systems, Varian has played a pivotal role in advancing adaptive radiation therapy and AI-driven treatment workflows. Its integration with Siemens has further enhanced its R&D capabilities and global reach.

Elekta AB
Elekta is a prominent player specializing in advanced radiation therapy and radiosurgery systems. The company provides cutting-edge solutions such as the Versa HD and Unity MR-linac, which combine MRI imaging with real-time radiation delivery. Elekta's focus on precision oncology and integrated digital platforms has positioned it as a key innovator in the field. Its commitment to improving patient outcomes through technological advancements continues to shape the evolution of modern radiotherapy across North America.

Accuray Incorporated
Accuray is recognized for its CyberKnife and TomoTherapy systems, which deliver highly precise robotic and helical radiation therapy. These technologies enable non-invasive treatment of tumors anywhere in the body with sub-millimeter accuracy. Accuray’s emphasis on innovation in stereotactic radiosurgery and adaptive therapy has contributed significantly to expanding treatment options for complex cancers. The company remains dedicated to enhancing clinical efficiency and personalizing cancer care through continuous product development.

Top Strategies Used by Key Players

Product Innovation and Technological Advancement
Leading players prioritize continuous innovation to develop next-generation radiotherapy systems that offer higher precision, reduced treatment times, and improved patient outcomes. Companies are integrating artificial intelligence, real-time imaging, and robotic automation into their platforms to enhance treatment accuracy and streamline clinical workflows, reinforcing their competitive edge in the market.

Strategic Collaborations and Partnerships
To expand their market footprint and accelerate technology adoption, key players engage in strategic alliances with academic institutions, research organizations, and healthcare providers. These collaborations support clinical validation, data sharing, and co-development initiatives, fostering broader acceptance of advanced radiotherapy solutions across North America.

Expansion Through Mergers and Acquisitions
Major companies actively pursue mergers and acquisitions to consolidate their presence and diversify their product portfolios. By acquiring smaller firms with niche technologies or regional expertise, they enhance their service offerings and strengthen distribution networks, enabling faster penetration into emerging segments and geographies within the North American market.

RECENT HAPPENINGS IN THE MARKET

In February 2024, Varian Medical Systems launched its new AI-powered treatment planning solution designed to streamline radiation therapy workflows and improve dosimetry accuracy, reinforcing its leadership in smart oncology solutions.

In May 2024, Elekta announced a strategic partnership with a leading U.S.-based cancer research institute to integrate its MRI-guided radiation therapy platform into multi-center clinical trials, aiming to expand its clinical applications and adoption across academic centers.

In July 2024, Accuray Incorporated introduced an updated version of its CyberKnife system featuring enhanced robotic targeting capabilities, allowing for more precise treatment of moving tumors and strengthening its appeal among complex cancer specialists.

In September 2024, a joint venture was formed between two mid-sized radiotherapy equipment providers to consolidate resources and accelerate development of cost-effective radiation therapy systems tailored for community hospitals and ambulatory clinics.

In November 2024, a major U.S.-based hospital chain signed a long-term agreement with a leading radiotherapy vendor to deploy next-generation linear accelerators across multiple facilities, boosting access to advanced treatments while securing consistent revenue for the supplier.

MARKET SEGMENTATION

This research report on the North American Radiotherapy market has been segmented and sub-segmented into the following categories

By Type

• External Beam Radiation Therapy
• Internal Beam Radiation Therapy
• Systemic Radiation Therapy

By Application

• Prostate Cancer
• Lung Cancer

By Equipment Type

• Linear Accelerators
• Treatment Planning Systems

By Country

• The U.S.
• Canada
• Rest of North America